Person · CIK 1614740

Christopher Peetz

CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals; director at Arcutis Biotherapeutics

Earlier: Alpine Immune Sciences and Tobira Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$27.6M
Noticed on Form 144$24M
Bought on Form 4$314K
Companies4

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Mirum Pharmaceuticals MIRMCommon StockDirectly206,637Nov 4, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRMCommon StockBy The Peetz Family Trust187,500Nov 4, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRMEmployee Stock Option (right to buy)
exercise $2.94, expires Mar 11, 2029, into Common Stock
Directly38,487Nov 4, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQTCommon StockDirectly4,315Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQTCommon StockBy The Peetz Family Trust187,500Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQTStock Option (right to buy)
exercise $27.78, expires Jul 15, 2036, into Common Stock
Directly21,486Jul 15, 2026 · Filing · EDGAR
Arcutis Biotherapeutics ARQTStock Option (right to buy)
exercise $27.78, expires Jul 15, 2036, into Common Stock
Directly13,010Jul 15, 2026 · Filing · EDGAR
Alpine Immune SciencesCommon StockChristopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust1,900Sep 23, 2021 · Filing · EDGAR
Alpine Immune SciencesCommon StockChristopher Peetz and Christine Peetz TR UA 02/15/2017 The Peetz Living Trust1,900Sep 23, 2021 · Filing · EDGAR

Sold and noticed by quarter

Christopher Peetz: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$7.4M$0Q1 2021: $0 noticed on Form 144Q1 2021: $0 sold on Form 4Q2 2021: $0 noticed on Form 144Q2 2021: $0 sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q3 2021: $19K boughtQ4 2021: notice not machine-readableQ4 2021: $71K sold on Form 4Q4 2021: $101K boughtQ1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: notice not machine-readableQ1 2023: $106K sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $141K sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $304K sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $0 sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $1.9M noticed on Form 144Q1 2025: $4.2M sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $4.7M noticed on Form 144Q3 2025: $4.7M sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $5.4M noticed on Form 144Q1 2026: $6M sold on Form 4Q2 2026: $2.9M noticed on Form 144Q2 2026: $2.9M sold on Form 4Q3 2026: $7.4M noticed on Form 144Q3 2026: $7.4M sold on Form 4Q4 2026: $1.8M noticed on Form 144Q4 2026: $1.8M sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)Bought (Form 4)
Q4 2026$1.8M$1.8M—
Q3 2026$7.4M$7.4M—
Q2 2026$2.9M$2.9M—
Q1 2026$6M$5.4M—
Q3 2025$4.7M$4.7M—
Q1 2025$4.2M$1.9M—
Q1 2024$304K——
Q3 2023$141K——
Q1 2023$106KNot machine-readable—
Q4 2021$71KNot machine-readable$101K
Q3 2021——$19K
Q4 2020——$93K
Q3 2019——$100K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 2, 2026 · 5 notices
Nov 4, 202620,000 · ~$1.8MNov 4, 2026Sold as noticed Sold 20,000 at $90.00 on Nov 4 · $1.8M Form 4Filing · EDGAR
Sep 1, 202630,000 · ~$3MSep 1, 2026Sold as noticed Sold 30,000 in 2 sales, Sep 1 to Sep 1 · $3M Form 4Filing · EDGAR
Aug 10, 202620,000 · ~$2MAug 10, 2026Sold as noticed Sold 20,000 in 3 sales, Aug 10 to Aug 10 · $2M Form 4Filing · EDGAR
Jul 6, 202620,000 · ~$2.4MJul 6, 2026Sold as noticed Sold 20,000 in 4 sales, Jul 6 to Jul 6 · $2.4M Form 4Filing · EDGAR
Jun 1, 202630,000 · ~$2.9MJun 1, 2026Sold as noticed Sold 30,000 in 6 sales, Jun 1 to Jun 1 · $2.9M Form 4Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 31, 2023 · 2 notices
Mar 17, 202640,985 · ~$3.8MMar 16, 2026Sold as noticed Sold 40,985 at $91.98 on Mar 16 · $3.8M Form 4Filing · EDGAR
Feb 2, 20269,108 · ~$945KFeb 2, 2026Sold as noticed Sold 9,108 at $103.30 on Feb 2 · $941K Form 4Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 23, 2024 · 1 notice
Jan 28, 20266,831 · ~$662KJan 26, 2026Sold as noticed Sold 6,831 at $96.19 on Jan 26 · $657K Form 4Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 22, 2024 · 3 notices
Aug 11, 202540,000 · ~$2.5MAug 11, 2025Sold as noticed Sold 40,000 at $62.00 on Aug 11 · $2.5M Form 4Filing · EDGAR
Aug 7, 202540,000 · ~$2.2MAug 7, 2025Sold as noticed Sold 40,000 at $55.25 on Aug 7 · $2.2M Form 4Filing · EDGAR
Mar 3, 202540,000 · ~$1.9MMar 3, 2025Sold as noticed Sold 40,000 in 2 sales, Mar 3 to Mar 3 · $1.9M Form 4Filing · EDGAR
Sales without a matching Form 144 · 10 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 7,098 at $93.33 on Jan 22, 2026 · $662KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 27,279 at $44.21 on Mar 17, 2025 · $1.2MFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 9,102 at $48.22 on Feb 3, 2025 · $439KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 6,837 at $47.92 on Jan 24, 2025 · $328KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 7,489 at $42.82 on Jan 7, 2025 · $321KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 6,013 at $26.19 on Feb 2, 2024 · $157KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 5,209 at $28.03 on Jan 8, 2024 · $146KFiling · EDGAR
———Sold without notice Mirum Pharmaceuticals (MIRM): Sold 5,498 at $25.65 on Jul 3, 2023 · $141KFiling · EDGAR
———Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 5,159 at $20.62 on Jan 9, 2023 · $106KFiling · EDGAR
———Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 3,672 at $19.26 on Oct 1, 2021 · $71KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Mirum Pharmaceuticals MIRM Chief executive officer · filings 2019 to 2026 · sold $27.6M · bought $294K · $24M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Nov 4, 2026Option or RSU exercised or converted+20,000$2.94$59K226,637 directFiling · EDGAR
Nov 4, 2026Sale under a 10b5-1 plan−20,000$90.00$1.8M206,637 directFiling · EDGAR
Nov 4, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−20,00038,487 directFiling · EDGAR
Oct 6, 2026Option or RSU exercised or converted+5,305$19.19$102K199,745 directFiling · EDGAR
Oct 6, 2026Option or RSU exercised or converted+6,892$15.87$109K206,637 directFiling · EDGAR
Oct 6, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−5,305169,695 directFiling · EDGAR
Oct 6, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−6,892233,108 directFiling · EDGAR
Sep 1, 2026Option or RSU exercised or converted+30,000$2.94$88K224,440 directFiling · EDGAR
Sep 1, 2026Sale under a 10b5-1 plan−8,312$98.08$815K216,128 directFiling · EDGAR
Sep 1, 2026Sale under a 10b5-1 plan−21,688$98.91$2.1M194,440 directFiling · EDGAR
Sep 1, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−30,00058,487 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted+20,000$2.94$59K214,309 directFiling · EDGAR
Aug 10, 2026Sale under a 10b5-1 plan−11,683$98.51$1.2M202,626 directFiling · EDGAR
Aug 10, 2026Sale under a 10b5-1 plan−6,017$99.25$597K196,609 directFiling · EDGAR
Aug 10, 2026Sale under a 10b5-1 plan−2,300$100.14$230K194,309 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−20,00088,487 directFiling · EDGAR
Jul 6, 2026Option or RSU exercised or converted+20,000$2.94$59K214,309 directFiling · EDGAR
Jul 6, 2026Sale under a 10b5-1 plan−12,134$121.65$1.5M202,175 directFiling · EDGAR
Jul 6, 2026Sale under a 10b5-1 plan−4,181$122.34$512K197,994 directFiling · EDGAR
Jul 6, 2026Sale under a 10b5-1 plan−1,975$123.74$244K196,019 directFiling · EDGAR
Jul 6, 2026Sale under a 10b5-1 plan−1,710$124.79$213K194,309 directFiling · EDGAR
Jul 6, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−20,000108,487 directFiling · EDGAR
Jun 1, 2026Option or RSU exercised or converted+30,000$2.94$88K224,309 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−2,602$94.64$246K221,707 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−16,595$95.34$1.6M205,112 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−6,926$96.15$666K198,186 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−1,973$97.56$192K196,213 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−1,021$98.20$100K195,192 directFiling · EDGAR
Jun 1, 2026Sale under a 10b5-1 plan−883$99.66$88K194,309 directFiling · EDGAR
Jun 1, 2026Option or RSU exercised or converted
Employee Stock Option (right to buy)
−30,000128,487 directFiling · EDGAR
Mar 16, 2026Open-market or private sale−40,985$91.98$3.8M194,309 directFiling · EDGAR
Mar 15, 2026Option or RSU exercised or converted+25,000185,294 directFiling · EDGAR
Mar 15, 2026Option or RSU exercised or converted+50,000235,294 directFiling · EDGAR
Mar 15, 2026Option or RSU exercised or converted
Performance Restricted Stock Units
−25,0000 directFiling · EDGAR
Mar 15, 2026Option or RSU exercised or converted
Performance Restricted Stock Units
−50,00025,000 directFiling · EDGAR
Feb 2, 2026Open-market or private sale−9,108$103.30$941K160,294 directFiling · EDGAR
Jan 28, 2026Grant or award from the company
Stock Option (right to buy)
+67,00067,000 directFiling · EDGAR
Jan 28, 2026Grant or award from the company
Restricted Stock Units
+43,50043,500 directFiling · EDGAR
Jan 28, 2026Grant or award from the company
Performance Restricted Stock Units
+75,00075,000 directFiling · EDGAR
Jan 26, 2026Open-market or private sale−6,831$96.19$657K169,402 directFiling · EDGAR
Jan 23, 2026Option or RSU exercised or converted+12,500176,233 directFiling · EDGAR
Jan 23, 2026Option or RSU exercised or converted
Restricted Stock Units
−12,50012,500 directFiling · EDGAR
Jan 22, 2026Open-market or private sale−7,098$93.33$662K163,733 directFiling · EDGAR
Jan 21, 2026Option or RSU exercised or converted+12,797170,831 directFiling · EDGAR
Jan 21, 2026Option or RSU exercised or converted
Restricted Stock Units
−12,79725,593 directFiling · EDGAR
Dec 31, 2025Gift−21,070187,500
By The Peetz Family Trust
Filing · EDGAR
Nov 18, 2025Option or RSU exercised or converted+19,133$19.24$368K158,034 directFiling · EDGAR
Nov 18, 2025Option or RSU exercised or converted
Employee Stock Option (right to buy)
−19,133150,867 directFiling · EDGAR
Aug 11, 2025Option or RSU exercised or converted+40,000$2.94$117K178,641 directFiling · EDGAR
Aug 11, 2025Sale under a 10b5-1 plan−40,000$62.00$2.5M138,641 directFiling · EDGAR
Aug 11, 2025Option or RSU exercised or converted
Employee Stock Option (right to buy)
−40,000158,487 directFiling · EDGAR
Aug 7, 2025Option or RSU exercised or converted+40,000$2.94$117K178,641 directFiling · EDGAR
Aug 7, 2025Sale under a 10b5-1 plan−40,000$55.25$2.2M138,641 directFiling · EDGAR
Aug 7, 2025Option or RSU exercised or converted
Employee Stock Option (right to buy)
−40,000198,487 directFiling · EDGAR
Mar 17, 2025Open-market or private sale−27,279$44.21$1.2M138,641 directFiling · EDGAR
Mar 15, 2025Option or RSU exercised or converted+50,000165,920 directFiling · EDGAR
Mar 15, 2025Option or RSU exercised or converted
Performance Restricted Stock Units
−50,00025,000 directFiling · EDGAR
Mar 3, 2025Option or RSU exercised or converted+40,000$2.94$117K155,920 directFiling · EDGAR
Mar 3, 2025Sale under a 10b5-1 plan−19,392$46.61$904K136,528 directFiling · EDGAR
Mar 3, 2025Sale under a 10b5-1 plan−20,608$47.19$972K115,920 directFiling · EDGAR

38 earlier transactions are in the filing list below.

Arcutis Biotherapeutics ARQT Director · filings 2026 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jul 15, 2026Grant or award from the company+4,3154,315 directFiling · EDGAR
Jul 15, 2026Grant or award from the company
Stock Option (right to buy)
+21,48621,486 directFiling · EDGAR
Jul 15, 2026Grant or award from the company
Stock Option (right to buy)
+13,01013,010 directFiling · EDGAR

Alpine Immune Sciences Director · filings 2018 to 2024 · bought $19K

DateTransactionSharesPriceValueHeld afterSource
May 20, 2024Returned to the company−1,900$0.00$20
Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust
Filing · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−7,6500 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−7,6500 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−7,6500 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−7,6500 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−10,0000 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−10,0000 directFiling · EDGAR
May 20, 2024Returned to the company
Stock Option (Right to buy)
−17,5000 directFiling · EDGAR
Jan 2, 2024Grant or award from the company
Stock Option (Right to buy)
+17,50017,500 directFiling · EDGAR
Jan 3, 2023Grant or award from the company
Stock Option (Right to buy)
+10,00010,000 directFiling · EDGAR
Jan 3, 2022Grant or award from the company
Stock Option (Right to buy)
+10,00010,000 directFiling · EDGAR
Sep 23, 2021Open-market or private purchase+1,900$10.17$19K1,900
Christopher Peetz and Christine Peetz TR UA 02/15/2017 The Peetz Living Trust
Filing · EDGAR
Sep 23, 2021Open-market or private sale+1,900$10.17$19K1,900
Christopher Peetz & Christine Peetz TR UA 02/15/2017 The Peetz Living Trust
Filing · EDGAR
Jan 4, 2021Grant or award from the company
Stock Option (Right to buy)
+7,6507,650 directFiling · EDGAR
Jan 2, 2020Grant or award from the company
Stock Option (Right to buy)
+7,6507,650 directFiling · EDGAR
Jan 2, 2019Grant or award from the company
Stock Option (Right to buy)
+7,6507,650 directFiling · EDGAR
Apr 20, 2018Grant or award from the company
Stock Option (right to buy)
+7,6507,650 directFiling · EDGAR

Tobira Therapeutics Chief Financial Officer · filings 2015 to 2016

DateTransactionSharesPriceValueHeld afterSource
Nov 1, 2016Returned to the company
Employee Stock Option (Right to Buy)
−68,7320 directFiling · EDGAR
Nov 1, 2016Returned to the company
Employee Stock Option (Right to Buy)
−31,0910 directFiling · EDGAR
Nov 1, 2016Returned to the company
Employee Stock Option (Right to Buy)
−85,0000 directFiling · EDGAR
Nov 1, 2016Returned to the company
Employee Stock Option (Right to Buy)
−101,0000 directFiling · EDGAR
Jan 12, 2016Grant or award from the company
Stock Options (right to buy)
+101,000101,000 directFiling · EDGAR
May 15, 2015Grant or award from the company
Stock Options (right to buy)
+85,00085,000 directFiling · EDGAR
May 6, 2015Grant or award from the company
Stock Options (right to buy)
+68,73268,732 directFiling · EDGAR
May 6, 2015Grant or award from the company
Stock Options
+31,09199,823 directFiling · EDGAR
All 72 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Nov 4, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Nov 4, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Oct 6, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Sep 3, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Sep 1, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 11, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 10, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Jul 17, 2026Form 4Arcutis Biotherapeutics ARQTFiling · EDGAR
Jul 17, 2026Form 3Arcutis Biotherapeutics ARQTFiling · EDGAR
Jul 8, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jul 6, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Jun 2, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jun 1, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 17, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 17, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Feb 3, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Feb 2, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 30, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 28, 2026Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 27, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 23, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 2, 2026Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Nov 20, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 12, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 11, 2025Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 8, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Aug 7, 2025Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 18, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 4, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 3, 2025Form 144Mirum Pharmaceuticals MIRMFiling · EDGAR
Feb 4, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 27, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 23, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 8, 2025Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Nov 14, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jul 24, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
May 20, 2024Form 4Alpine Immune SciencesFiling · EDGAR
May 16, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Mar 18, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Feb 5, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 25, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 9, 2024Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 4, 2024Form 4Alpine Immune SciencesFiling · EDGAR
Jul 5, 2023Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
May 19, 2023Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Feb 2, 2023Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 5, 2023Form 4Alpine Immune SciencesFiling · EDGAR
Nov 14, 2022Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
May 12, 2022Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 7, 2022Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 4, 2022Form 4Alpine Immune SciencesFiling · EDGAR
Nov 29, 2021Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Oct 1, 2021Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Sep 27, 2021Form 4/AAlpine Immune SciencesFiling · EDGAR
Sep 24, 2021Form 4Alpine Immune SciencesFiling · EDGAR
May 12, 2021Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 11, 2021Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 5, 2021Form 4Alpine Immune SciencesFiling · EDGAR
Dec 28, 2020Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Nov 12, 2020Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 14, 2020Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 6, 2020Form 4Alpine Immune SciencesFiling · EDGAR
Sep 10, 2019Form 4Mirum Pharmaceuticals MIRMFiling · EDGAR
Jul 17, 2019Form 3Mirum Pharmaceuticals MIRMFiling · EDGAR
Jan 4, 2019Form 4Alpine Immune SciencesFiling · EDGAR
Apr 24, 2018Form 4Alpine Immune SciencesFiling · EDGAR
Apr 24, 2018Form 3Alpine Immune SciencesFiling · EDGAR
Nov 3, 2016Form 4Tobira TherapeuticsFiling · EDGAR
Jan 14, 2016Form 4Tobira TherapeuticsFiling · EDGAR
May 18, 2015Form 4Tobira TherapeuticsFiling · EDGAR
May 6, 2015Form 4Tobira TherapeuticsFiling · EDGAR
May 6, 2015Form 3Tobira TherapeuticsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.